Skip to content

DE · QIA.DE · MEDICAL - DIAGNOSTICS & RESEARCH

Qiagen N.V. (QIA.DE) intrinsic value and stock valuation

$45.07as of 2026-11-21 · Mkt cap 6.37B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Qiagen N.V. DCF and intrinsic value

InvestorsCraft values QIA.DE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from QIA.DE’s statements →

Qiagen N.V. Graham Number

Graham Number: $28.90d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Venlo 5912 PL qiagen.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.09B+2.2% 5y CAGRd
20112025
Net income
$424.9M+42% 5y CAGRd
20112025
Free cash flow
$453.3M+19.2% 5y CAGRd
20112025
Total equity
$3.78B+8.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.09B$1.98B$1.97B$2.14B$2.25B
Operating income$520.4M$97.7M$409.9M$531.5M$630.1M
Net income$424.9M$83.6M$341.3M$423.2M$512.6M
EPSd$2.04M$382.6K$1.57M$1.95M$2.34M
Operating cash flow$654.4M$673.6M$459.5M$715.3M$639M
Capital expenditure-$-201.06M-$-167.17M-$-162.8M-$-149.34M-$-206.53M
Free cash flow$453.3M$506.4M$296.7M$565.9M$432.5M
Total assets$6.3B$5.69B$6.12B$6.29B$6.15B
Total debt$1.65B$1.51B$1.53B$1.86B$1.98B
Net debt$815.5M$849M$864M$1.13B$1.06B
Total equity$3.78B$3.57B$3.81B$3.47B$3.1B
Cash and short-term investments$1.1B$1.15B$1.06B$1.42B$1.07B
Income statement
20252024202320222021
Revenue$2.09B$1.98B$1.97B$2.14B$2.25B
Cost of revenue$798.6M$653.4M$731.6M$757M$733.7M
Gross profit$1.29B$1.32B$1.23B$1.38B$1.52B
Research and development expenses$187.5M$193.5M$198.5M$189.9M$190M
Selling, general and administrative expenses$583.7M$564.4M$579.2M$604M$584.5M
Other expenses$0.00$469.2M$46.1M$59.3M$113.4M
Operating expenses$771.2M$1.23B$823.8M$853.1M$887.9M
Cost and expenses$1.57B$1.88B$1.56B$1.61B$1.62B
Interest income$64.3M$68M$79M$32.8M$9.55M
Interest expense$33.3M$43.8M$53.4M$58.4M$54.5M
Depreciation and amortization$193.8M$203.3M$205.3M$208.4M$214.9M
Ebitda$717.3M$702.1M$688.6M$779.4M$895.2M
Operating income$520.4M$97.7M$409.9M$531.5M$630.1M
Total other income/expenses, net-$-30.05M$23.4M$19.9M-$-18.86M-$-4.25M
Income before tax$490.3M$121.2M$429.8M$512.6M$625.8M
Income tax expense$65.4M$37.6M$88.5M$89.4M$113.2M
Net income$424.9M$83.6M$341.3M$423.2M$512.6M
Weighted average shares outstanding$207.9M$216.4M$215.2M$214.6M$215M
Weighted average diluted shares outstanding$207.9M$218.5M$217.5M$217M$218.8M
Balance sheet
20252024202320222021
Cash and short-term investments$1.1B$1.15B$1.06B$1.42B$1.07B
Net receivables$402.6M$459M$515.6M$333.5M$469.7M
Inventory$301.9M$279.3M$398.4M$358M$327.5M
Total current assets$2B$1.96B$2.15B$2.39B$2.11B
Property, plant and equipment, net$924M$753.6M$870.3M$662.2M$638.2M
Goodwill and intangible assets$3.09B$2.73B$3B$2.9B$2.98B
Long-term investments$0.00$19.3M$23.7M$23.6M$0.00
Total non-current assets$4.3B$3.73B$3.97B$3.89B$4.04B
Total assets$6.3B$5.69B$6.12B$6.29B$6.15B
Accounts payable$72.7M$83.3M$84.2M$98.7M$101.2M
Short-term debt$0.00$77.8M$610.2M$411.8M$869.7M
Deferred revenue$0.00$0.00$0.00$69M$63.4M
Total current liabilities$512.2M$543.6M$1.08B$974.5M$1.52B
Long-term debt$1.65B$1.43B$1.1B$1.58B$1.24B
Deferred revenue, non-current$0.00$18M$15.6M$15.2M$11.3M
Total non-current liabilities$2.01B$1.58B$1.23B$1.85B$1.53B
Capital lease obligations$0.00$121M$101.3M$93.6M$98.6M
Total liabilities$2.52B$2.12B$2.31B$2.82B$3.05B
Common stock$2.53M$2.6M$2.7M$2.7M$2.7M
Retained earnings$2.75B$2.45B$2.46B$2.16B$1.79B
Accumulated other comprehensive income (loss)-$-377.33M-$-474.54M-$-433.83M-$-404.09M-$-326.67M
Total equity$3.78B$3.57B$3.81B$3.47B$3.1B
Total investments$259.9M$508.7M$413.4M$711.1M$184.8M
Total debt$1.65B$1.51B$1.53B$1.86B$1.98B
Net debt$815.5M$849M$864M$1.13B$1.06B
Cash flow statement
20252024202320222021
Net income$424.9M$83.6M$341.3M$423.2M$512.6M
Depreciation and amortization$193.8M$221.7M$205.3M$208.4M$214.9M
Stock-based compensation$0.00$43.6M$47.1M$49.5M$38.4M
Change in working capital-$-34.52M$135.5M-$-186.96M-$-31.88M-$-130.01M
Accounts receivable-$-36.39M$12.2M-$-55.12M$15.5M-$-7.4M
Inventory-$-850K$87.8M-$-44.79M-$-61.95M-$-81.8M
Accounts payable-$-8.42M$1.45M-$-22.42M-$-1.76M-$-5.97M
Net cash provided by operating activities$654.4M$673.6M$459.5M$715.3M$639M
Investments in property, plant and equipment-$-207.14M-$-167.17M-$-149.71M-$-149.34M-$-206.53M
Acquisitions, net-$-291.25M$0.00-$-149.53M-$-63.65M-$-16.63M
Net cash used for investing activities-$-305.3M-$-249.23M-$-87.66M-$-726.76M-$-202.43M
Common stock issued$0.00$0.00$36.9M$120K$7.92M
Common stock repurchased-$-280.11M-$-326.26M-$-17.68M-$-25.36M-$-99.99M
Dividends paid-$-54.25M$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-178.99M-$-422.9M-$-433.83M-$-125.8M-$-150.37M
Net change in cash$86.2M-$-4.53M-$-62.59M-$-149.85M$282.5M
Cash at end of period$839.1M$663.6M$668.1M$730.7M$880.5M
Operating cash flow$654.4M$673.6M$459.5M$715.3M$639M
Capital expenditure-$-201.06M-$-167.17M-$-162.8M-$-149.34M-$-206.53M
Free cash flow$453.3M$506.4M$296.7M$565.9M$432.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Qiagen N.V.

        QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

        CEO
        Thierry L. Bernard
        Employees
        5.7K
        Beta
        0.64

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Qiagen N.V. (QIA.DE)?

        InvestorsCraft does not currently publish an intrinsic value for QIA.DE. How the IC value is calculated.

        Is QIA.DE undervalued?

        InvestorsCraft does not publish an undervaluation signal for QIA.DE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.